Filing Details

Accession Number:
0001214659-22-000855
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-18 20:32:37
Reporting Period:
2022-01-14
Accepted Time:
2022-01-18 20:32:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX Pharmaceutical Preparations (2834) 462693615
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753055 Benjamin Hickey C/O Mirati Therapeutics
3545 Cray Court
San Diego CA 92121
Evp, Chief Commercial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-14 10,755 $0.00 35,603 No 4 A Direct
Common Stock Disposition 2022-01-18 627 $120.48 34,976 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Acquisiton 2022-01-14 17,821 $0.00 17,821 $124.31
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
17,821 2032-01-13 No 4 A Direct
Footnotes
  1. Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
  2. Represents shares sold by the Company to satisfy the tax withholding obligation associated with the vesting of a portion of the restricted stock units (RSUs) granted on January 15, 2021.
  3. The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $120.2091 to $120.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  4. 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.